Executive Spotlights
Talent Trends
Top Industry Lists
Showcase your Innovations
Backed by Bayer, Senti Biosciences Snags $105 Million in Series B Fundraising
Biomarck Appoints Graham Lumsden as President and Chief Executive Officer
Ribometrix and Genentech Partner in Potential $1Billion+ RNA Deal
in Why I Work in Healthcare
Why I Work In Healthcare
by hsandm August 1, 2018, 12:00 pm
in Great Minds
Great Advice From Great Minds: Takeda Head of Commercial Learning and Development: Breaking Down Silos
in Industry Trends
INDUSTRY TRENDS : BY THE NUMBERS
in Round Table
AARP on older adults' digital habits and attitudes on healthcare companies
in Top Industry Lists
REVENUES CONTINUE TO RISE: THE TOP 50 PHARMA COMPANIES
in Motivideos
WE ARE MAKING HS&M'S SERIES OF TOP COMPANY LISTS AVAILABLE BELOW.
Accenture Advice and AstraZeneca Case History On the Power of Patient Services
The Rep of the Future
What if Dr. House Used Twitter?
MOTIVIDEOS
Sales Strategy: Viewpoints from MDcentRx, Sunovion PTC Therapeutics and Wipro Execs
in Executive Spotlight
Executive Spotlight: Otsuka and Spark Therapeutics CEOs on Marketing Firsts in Digital and Gene Therapy
Leverkusen, Germany & South San Francisco, CA, January 6 2021 (Business Wire) — Leaps by Bayer and Senti Biosciences, Inc., a leading gene circuit company, today announced a USD 105 million Series B financing round. The financing was led by Leaps by Bayer, the impact investment arm of Bayer AG. Additional investors included Matrix Partners China, Mirae Asset Capital, Ridgeback Capital and Intel Capital as well as existing investors, including New Enterprise Associates (NEA), 8VC, Amgen Ventures and Lux Capital. More
by hsandm January 6, 2021, 10:15 pm
Durham, NC, January 6 2021 (Business Wire) — Biomarck Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company developing anti-inflammatory and oncological therapies that target the MARCKS protein, today announced the appointment of Dr. Graham G. Lumsden as President and Chief Executive Officer. More
by hsandm January 6, 2021, 9:59 pm
Durham, NC, January 6 2021 (Business Wire) — Ribometrix, Inc. today announced a strategic collaboration with Genentech, a member of the Roche Group, to discover and develop novel RNA-targeted small molecule therapeutics against several targets.
Ribometrix is focused on leveraging its RNA structural expertise and analytical capabilities to make the vast landscape of RNA, which is involved in a wide variety of disease processes, accessible to small molecule therapeutics
Artiva Biotherapeutics Announces Appointment of Dr. Fred Aslan as President and CEO
San Diego, CA, January 5 2021 (Bloomberg) — Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, announced today the appointment of Fred Aslan, M.D., as President and Chief Executive Officer. Dr. Aslan brings a twenty-year track record as an executive and investor in the life sciences industry. More
Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers, for Approximately $230 Million
Marlborough, MA , January 5 2021 (Business Wire) — Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has agreed to acquire Biotheranostics, Inc., a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million, subject to working capital and other customary closing adjustments. More
in Talent Trends
The Instant-On, On-Demand Workforce
How have the pandemic, IT advances, remote working, skill set requirements and other influences in these fast-changing times affected our strategies and practices in hiring? Quite a lot, and it's the responsibility of every company to keep up with the needs and opportunities that are before us. In addition, how do we deal with the […] More
by hsandm December 22, 2020, 2:43 am
© 2021 by CL Media, Inc.